Splicing in the immune system: Potential targets for therapeutic intervention by antisense-mediated alternative splicing

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 2, 2009, Pages 124-132

  Mourich, Dan V ^a,b   Iversen, Patrick L ^a  

^a AVI BIOPHARMA INC   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Autoimmunity; HIV; Immune regulation; Lymphocyte; Pre mRNA splicing

Indexed keywords

B7 ANTIGEN; CELL PENETRATING PEPTIDE; COMPLEMENTARY RNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DESMOGLEIN; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA PRECURSOR; RIBONUCLEASE H; STROMAL CELL DERIVED FACTOR 1;

ANTISENSE THERAPY; AUTOIMMUNITY; CELL DIFFERENTIATION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EUKARYOTE; EXON; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; PROTEIN TARGETING; REVIEW; RNA SPLICING;

ALTERNATIVE SPLICING; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; LYMPHOCYTES; MODELS, BIOLOGICAL; OLIGONUCLEOTIDES, ANTISENSE; RNA PRECURSORS;

EUKARYOTA;

EID: 63849286624     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Kim E, Magen A, Ast G: Different levels of alternative splicing among eukaryotes. Nucleic Acids Res (2007) 35(1):125-131.
2. Kim E, Goren A, Ast G: Alternative splicing: Current perspectives. Bioessays (2008) 30(1):38-47.
3. House AE, Lynch KW: Regulation of alternative splicing: More than just the ABCs. J Biol Chem (2008) 283(3):1217-1221.
4. Chang YF, Imam JS, Wilkinson MF: The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem (2007) 76:51-74.
5. Modrek B, Lee CJ: Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat Genet (2003) 34(2):177-180.
6. Lynch KW: Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev Immunol (2004) 4(12):931-940.
7. Valadkhan S: The spliceosome: Caught in a web of shifting interactions. Curr Opin Struct Biol (2007) 17(3):310-315.
8. Wang GS, Cooper TA: Splicing in disease: Disruption of the splicing code and the decoding machinery. Nat Rev Genet (2007) 8(10):749-761.
9. Solis AS, Shariat N, Patton JG: Splicing fidelity, enhancers, and disease. Front Biosci (2008) 13:1926-1942.
10. Faustino NA, Cooper TA: Pre-mRNA splicing and human disease. Genes Dev (2003) 17(4):419-437.
11. Sazani P, Kole R: Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest (2003) 112(4):481-486.
12. Aartsma-Rus A, van Ommen GJ: Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA (2007) 13(10):1609-1624.
13. Blencowe BJ: Alternative splicing: New insights from global analyses. Cell (2006) 126(1):37-47.
14. Ip JY, Tong A, Pan Q, Topp JD, Blencowe BJ, Lynch KW: Global analysis of alternative splicing during T-cell activation. RNA (2007) 13(4):563-572.
15. House AE, Lynch KW: An exonic splicing silencer represses spliceosome assembly after ATP-dependent exon recognition. Nat Struct Mol Biol (2006) 13(10):937-944.
16. Tong A, Nguyen J, Lynch KW: Differential expression of CD45 isoforms is controlled by the combined activity of basal and inducible splicing-regulatory elements in each of the variable exons. J Biol Chem (2005) 280(46):38297-38304.
17. Rothrock CR, House AE, Lynch KW: HnRNP L represses exon splicing via a regulated exonic splicing silencer. EMBO J (2005) 24(15):2792-2802.
18. Melton AA, Jackson J, Wang J, Lynch KW: Combinatorial control of signal-induced exon repression by hnRNP L and PSF. Mol Cell Biol (2007) 27(19):6972-6984.
19. Tchilian EZ, Wallace DL, Dawes R, Imami N, Burton C, Gotch F, Beverley PC: A point mutation in CD45 may be associated with an increased risk of HIV-1 infection. AIDS (2001) 15(14):1892-1894.
20. Tchilian EZ, Wallace DL, Wells RS, Flower DR, Morgan G, Beverley PC: A deletion in the gene encoding the CD45 antigen in a patient with SCID. J Immunol (2001) 166(2):1308-1313.
21. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R, Wonigeit K, Lindert RB, Kantarci O, Schaefer-Klein J, Schipper HI et al: A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet (2000) 26(4):495-499.
22. Schwinzer R, Witte T, Hundrieser J, Ehlers S, Momot T, Hunzelmann N, Krieg T, Schmidt RE, Wonigeit K: Enhanced frequency of a PTPRC (CD45) exon A mutation (77C→G) in systemic sclerosis. Genes Immun (2003) 4(2):168-169.
23. Vogel A, Strassburg CP, Manns MP: 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: Evidence for a genetic link. Genes Immun (2003) 4(1):79-81.
24. Nelson MH, Stein DA, Kroeker AD, Hatlevig SA, Iversen PL, Moulton HM: Arginine-rich peptide conjugation to morpholino oligomers: Effects on antisense activity and specificity. Bioconjug Chem (2005) 16(4):959-966.
25. Marshall NB, Oda SK, London CA, Moulton HM, Iversen PL, Kerkvliet NI, Mourich DV: Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Methods (2007) 325(1-2):114-126.
26. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH et al: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 423(6939):506-511.
27. Kuhns MS, Epshteyn V, Sobel RA, Allison JP: Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci USA (2000) 97(23):12711- 12716.
28. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 6(4):411-417.
29. Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 19:225-252.
30. Egen JG, Kuhns MS, Allison JP: CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 3(7):611-618.
31. Vijayakrishnan L, Slavik JM, Illes Z, Greenwald RJ, Rainbow D, Greve B, Peterson LB, Hafler DA, Freeman GJ, Sharpe AH, Wicker LS et al: An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity (2004) 20(5):563-575.
32. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, Baker B et al: Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 8(11):1246-1254.
33. Rac ME, Safranow K, Poncyljusz W: Molecular basis of human CD36 gene mutations. Mol Med (2007) 13(5-6):288-296.
34. Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, Harder B, Okada S, Ostrander CD, Kreindler JL, Aujla SJ et al: Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol (2007) 179(8):5462-5473.
35. Cortesini R: Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3). Jop (2007) 8(6):697-703.
36. Suciu-Foca N, Feirt N, Zhang QY, Vlad G, Liu Z, Lin H, Chang CC, Ho EK, Colovai AI, Kaufman H, D'Agati VD et al: Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol (2007) 178(11):7432-7441.
37. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escribano MF, Pons-Estel B, Petri M et al: A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet (2006) 38(5):550-555.
38. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC, Plenge RM, Koeuth T, Ortmann WA, Hom G, Bauer JW et al: Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA (2007) 104(16):6758-6763.
39. Kozyrev SV, Alarcon-Riquelme ME: The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity (2007) 40(8):591-601.
40. Zhang XJ, Yan KL, Wang ZM, Yang S, Zhang GL, Fan X, Xiao FL, Gao M, Cui Y, Wang PG, Sun LD et al: Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol (2007) 127(11):2544-2551.
41. Bulanova E, Budagian V, Duitman E, Orinska Z, Krause H, Ruckert R, Reiling N, Bulfone-Paus S: Soluble interleukin IL-15Ra is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J Biol Chem (2007) 282(18):13167-13179.
42. Sato N, Patel HJ, Waldmann TA, Tagaya Y: The IL-15/IL-15Ra on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci USA (2007) 104(2):588-593.
43. high T cells and its antitumor action. J Immunol (2008) 180(4):2099-2106.
44. Altenburg JD, Broxmeyer HE, Jin Q, Cooper S, Basu S, Alkhatib G: A naturally occurring splice variant of CXCL12/stromal cell-derived factor 1 is a potent human immunodeficiency virus type 1 inhibitor with weak chemotaxis and cell survival activities. J Virol (2007) 81(15):8140-8148.
45. Kakoulidou M, Giscombe R, Zhao X, Lefvert AK, Wang X: Human soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation. Scand J Immunol (2007) 66(5):529-537.
46. Yang S, Hu S, Choudhry MA, Rue LW 3rd, Bland KI, Chaudry IH: Anti-rat soluble IL-6 receptor antibody down-regulates cardiac IL-6 and improves cardiac function following traumahemorrhage. J Mol Cell Cardiol (2007) 42(3):620-630.
47. Serrano-Gomez D, Sierra-Filardi E, Martinez-Nunez RT, Caparros E, Delgado R, Munoz-Fernandez MA, Abad MA, Jimenez-Barbero J, Leal M, Corbi AL: Structural requirements for multimerization of the pathogen receptor dendritic cell-specific ICAM3-grabbing non-integrin (CD209) on the cell surface. J Biol Chem (2008) 283(7):3889-3903.
48. Mouquet H, Farci S, Joly P, Maillere B, Leblond J, Drouot L, Leprince J, Tonon MC, Loiseau P, Charron D, Tron F, Gilbert D: A truncated alternative spliced isoform of human desmoglein 1 contains a specific T cell epitope binding to the pemphigus foliaceus-associated HLA class II DRβ1*0102 molecule. J Immunol (2006) 177(9):6517-6526.